Intoxication with amphetamines and designer drugs;Intoxikation mit amphetaminen und designer-drogen

Internist

Volumn 40, Issue 6, 1999, Pages 617-623

  Felgenhauer, N ^a   Zilker, T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; AMPHETAMINIL; ANOREXIGENIC AGENT; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CLOMETHIAZOLE; DANTROLENE; DESIGNER DRUG; FENETYLLINE; FENFLURAMINE; METHAMPHETAMINE; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PEMOLINE; PHENMETRAZINE; PHENTERMINE RESIN; PROPRANOLOL DERIVATIVE; PSYCHEDELIC AGENT; PSYCHOSTIMULANT AGENT; SEROTONIN;

CHEMICAL ANALYSIS; DRUG INTOXICATION; DRUG STRUCTURE; EUPHORIA; HEMODIALYSIS; HUMAN; OBESITY; REVIEW; SEROTONINERGIC SYSTEM; SUBSTANCE ABUSE;

3,4-METHYLENEDIOXYAMPHETAMINE; AMPHETAMINES; DESIGNER DRUGS; HUMANS; INTERNAL MEDICINE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OVERDOSE; SEROTONIN SYNDROME; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 0033007698     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001080050379     Document Type: Review

References (50)

1. 1. Aghajanian GK (1994) LSD and phenethylamine hallucinogens: commen site of neuronal action. In: Pletscher A, Ladewig D (eds) 50 Years of LSD. Current status and perspectives of hallucinogens. Parthenon, New York London, pp 27-41
2. 2. Amercan Acadamy of Clinical Toxicology; European Association of Poison Centres and Clinical Toxicologists (1997) Position statement: gastric lavage. J Toxicol Clin Toxicol 35:711-719
3. 3. Ames D, Wirshing WC (1993) "Ecstasy", the serotonin syndrome and neuroleptic malignant syndrome-a possible link? J Am Med Ass 269:869-870
4. 4. Benazzi F, Mazzoli M (1991) Psychiatric illness associated with "ecstasy". Lancet 338:1520
5. 5. Brauer RB, Heidecke CD, Nathrath W, Beckurts KT, Vorwald P, Zilker TR, Schweigart U, Hölscher AH, Siewert JR (1997) Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. Transpl Int 10:229-233
6. 1 like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7:113-127
7. 7. Chance MRA (1947) Factors influencing the toxicity of sympathomimetic amines to solitary mice. J Pharmacol Exp Ther 89:289-296
8. 8. Davis JM, Kopin IJ, Lemberger L, Axelrod J (1971 ) Effects of urinary pH on amphetamine metabolism. Ann NY Acad Sci 179:493-501
9. 9. Dring LG, Smith RL, Williams RT (1966) The fate of amphetamine in man and other animals. J Pharm Pharmacol 18:402-405
10. 10. Ellenhorn MJ, Barceloux DG (1988) Amphetamines. In: Ellenhorn MJ, Barceloux DG (Hrsg) Medical toxicology: diagnosis and treatment of human poisoning. Elsevier, New York, Amsterdam, London pp 625-641
11. 11. Ellis AJ, Wendon JA, Portmann B, Williams R (1996) Acute liver damage and ecstasy ingestion. Gut 38:454-458
12. 12. Forth W, Henschler D, Rummel W, Starke K (Hrsg) (1992) In: Allgemeine und spezielle Pharmakologie und Toxikologie: für Studenten der Medizin, Veterinärmedizin, Pharmazie, Chemie, Biologie sowie für Ärzte,Tierärzte und Apotheker. BI-Wissenschaftsverlag, Mannheim Leipzig Wien Zürich, pp 296
13. 13. Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoidal haemorrhage assciated with MDMA abuse. J Neurol Neurosurg Psychiatry 56:1036-1037
14. 14. Goldfrank LR, Flomenbaum NE, Lewin NA et al. (1994) In: Goldrank's toxicologic emergencies. Appelton & Lange, Norwalk, pp 870
15. 15. Gouzoulis-Mayfrank E, Hermle L, Kovar KA, Saß H (1996) Die Entaktogene "Ecstasy" (MDMA), "Eve" (MDE) und andere ringsubstituierte Methamphetaminderivate. Nervenarzt 67:369-380
16. 16. Green AR, Cross AJ, Goodwin GM (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 119:247-260
17. 17. Guze BH, Baster LR (1986) Serotonin syndrome: case responsive to propranolol (letter). J Clin Psychopharmacol 6:119-120
18. 18. Harries DP, DeSilva R (1992) Ecstasy and intracerbral haemorrhage. Scot Med J 37:150-152
19. 19. Hasler R (1998) Rauschgiftlage 1997. In: Deutsche Hauptstelle gegen die Suchtgefahren (ed) Jahrbuch Sucht 1999. Neuland, Geesthacht, pp 72-88
20. 20. Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340:384-387
21. 21. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Fosling M (1998) Low-dose MDMA ("ecstasy") induces vasopressin secretion. Lancet 351:1784
22. 22. Hewitt KE, Green AR (1994) Clomethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("Ecstasy"). Neuropharmacology 33:1589-1595
23. 23. Hodding GC, Jann M, Ackerman IP (1980) Drug withdrawal syndromes. A literature review. West J Med 133:383-391
24. 24. Huether G, Zhou D, Rüther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. J Neural Transm 104:771-794
25. 25. Kalant H, Kalant OJ (1975) Death in amphetamine users. Causes and rates. Can Med Assoc J 112:299-304
26. 26. Kendrick WC, Hull AR, Knochel JP (1977) Rhabdomyolysis and shock after intravenous amphetamine administration. Ann Intern Med 86:381-387
27. 27. Kraus L, Töppich J (1998) Konsumtrend illegaler Drogen bei Jugendlichen und Erwachsenen in Deutschland 1973 bis 1997. In: Deutsche Hauptstelle gegen die Suchtgefahren (ed) Jahrbuch Sucht 1999. Neuland, Geesthacht, pp 129-153
28. 28. Lappin R, Auchincloss E (1994) Treatment of serotonin syndrome with cyproheptadine. N Engl J Med 331:1021-1022
29. 29. Logan BK, Fligner CL, Haddix T (1998) Cause and manner of death in fatalities involving methamphetamine. J Forensic Sci 43:28-34
30. 30. Martin TG (1996) Serotonin syndrome. Ann Emerg Med 28:520-526
31. 31. McGuire PK, Cope H, Fahy TA (1994) Diversity of psychopathology associated with use of 3,4-methylenedioxymethamphetamin ("Ecstasy"). Br J Psychiatry 165:391-395
32. 32. McKenna DJ, Peroutka SJ (1990) Neurochemistry and neurotoxicity of 3,4-methylendioxymethamphetamine (MDMA, "Ecstasy"). J Neurochem 54:14-22
33. 33. McKetin R, Mattick RP (1998) Attention and memory in illicit amphetamine users: comparison with non-drug-using controls. Drug Alcohol Depend 50:181-184
34. 34. Molliver ME, Berger UV, Mamounas LA, Molliver DL, O'Hearn E, Wilson MA (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann NY Acad Sci 600:640-661
35. 35. Mueller PD, Korey WS (1998) Death by "ecstasy": the serotonin syndrom? Ann Emerg Med 32:377-380
36. 36. Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamin in recreational users. Neuropsychopharmacology 1:273-277
37. 37. Richards JR, Derlet RW, Duncan DR (1997) Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med 4:130-135
38. 38. Rowland M (1969) Amphetamine blood and urine levels in man. J Pharm Sci 4:508-509
39. 39. Sandyk R (1986) L-Dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 6:194-195
40. 40. Sauer O, Weilemann LS (1997) Psychogene Amphetamine ("Ecstasy"). Intensivmed 34:5-13
41. 41. Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J Pharmacol Exp Ther 240:1-7
42. 2 receptors. Brain Res 529:85-90
43. 43. Schwartz RH, Miller NS (1997) MDMA (Ecstasy) and the rave: a review. Pediatrics 100:705-708
44. 44. Slikker W jr, Holson RR, Ali SF, Kolta MG, Paule MG, Scallet AC, McMillan DE, Bailey JR, Hong JS, Scalzo FM (1989) Behavioural and neurochemical effects of orally administered MDMA in the rodent and nonhuman primate. Neurotoxicology 19:529-542
45. 45. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine [(+)-MDMA] on locomotion and serotonin syndrome behaviour in the rat. Pharmacol Biochem Behav 32:835-840
46. 46. Sporer KA (1995) The serotonin syndrome: implicated drugs, pathophysiology and management. Drug Safety 13:94-104
47. 47. Stone DM, Merchant KM, Hanson GR, Gibb JW (1987) Immediate and long term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 26:1677-1683
48. 48. Whitaker-Azmitia PM, Aronson TA (1989) "Ecstasy" (MDMA)-induced panic (letter). Am J Psychiatry 146:119
49. 49. Winstock AR (1991) Chronic paranoid psychosis after misuse of MDMA. BMJ 302:1150-1151
50. 50. Zalis EG, Parmley LF (1963) Fatal amphetamine poisoning. Arch Intern Med 101:822-826